FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 112 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Prefrail and Frail Young Adult Survivors of Childhood Cancers Experience Significant... July 22, 2021 Building Your Fort of Support: Tips from a Breast Cancer Social... October 27, 2021 The (un)usual suspects – how early detection research embraces interdisciplinary science August 20, 2021 Being Diagnosed With a Childhood Cancer As an Adult Led Me... May 18, 2023 Load more HOT NEWS Maximizing the Prospects for Progress Against Cancer Cancer in Lymph Nodes May Help Tumors Spread by Enlisting Immune... ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European... New Type of Chemotherapy Bypasses Healthy Cells to Decrease Negative Side...
